Viromed Medical AG

Viromed Medical AG’s €6.60 stock reflects biotech volatility—52‑week high €8.45, low €1.62, €67.6M cap—showing investor risk, opportunity, and future potential.

Viromed Medical AG’s €6.00 stock shows sharp volatility—mid‑point between a €8.45 peak and €1.62 low—while awaiting new data on its cold‑plasma‑based lung therapy.

Viromed Medical AG teases breakthrough cold‑plasma therapy for lung care, amid sharp stock swings; investors eye February press conference for next‑step insights.

Viromed Medical AG: Explore its recent shift to common shares, stable €4.08 price, high P/E, and cutting‑edge cold‑plasma tech poised for growth in healthcare.

Viromed Medical AG’s 15 Jan 2026 update: registered share conversion, new ISIN, key executive sale disclosed, and PulmoPlas milestone forecast—enhancing transparency and growth prospects.

Viromed Medical AG, a leading healthcare company, is making significant strides in wound healing technology, with a strong market presence and focus on innovation, positioning it for continued success and growth.